Genome Biologics
Phase 2Genome Biologics provides cardiotoxicity screening, disease modeling, and multi-omics profiling services using TrueCardium® human cardiac organoids for predictive cardiovascular drug development.
Founded
2017
Focus
AI / Machine Learning
About
Genome Biologics provides cardiotoxicity screening, disease modeling, and multi-omics profiling services using TrueCardium® human cardiac organoids for predictive cardiovascular drug development.
Funding History
2Total raised: $21.8M
Series A$18MGerman BioFundAug 15, 2022
Seed$3.8MBioStart IncubatorApr 15, 2020
Company Info
TypePrivate
Founded2017
LocationMunich, Germany
StagePhase 2
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile